Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

March 2012

Palatin Technologies Completes Enrollment in Phase 2B Bremelanotide Female Sexual Dysfunction Trial

Press Releases / By

CRANBURY, N.J., March 8, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced it has completed enrollment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).  Over 400 premenopausal women, diagnosed with female sexual arousal disorder, hypoactive sexual desire disorder or both, have …

Palatin Technologies Completes Enrollment in Phase 2B Bremelanotide Female Sexual Dysfunction Trial Read More »

Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference

Press Releases / By

CRANBURY, N.J., March 7, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 24th Annual ROTH OC Growth Stock Conference on Tuesday, March 13, 2012, at 1:30 p.m. Pacific Time.  The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Carl Spana, …

Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference Read More »

Scroll to Top